To characterize the independent effect of antidepressants on glioblastoma survival while accounting for specific molecular factors (e.g., IDH mutation status, MGMT methylation) and socioeconomic factors (e.g., insurance status, neighborhood deprivation).
Key Findings:
Disproportionately high rates of depression occur in glioblastoma patients, impacting survival, with nearly 40% affected.
Antidepressant therapy may improve patient function and adherence to treatment, though results are mixed in existing literature.
Previous studies show conflicting results regarding the impact of antidepressants on glioblastoma survival, necessitating further investigation.
Interpretation:
The study aims to clarify the relationship between antidepressant use and glioblastoma survival, considering socioeconomic and molecular factors that have not been thoroughly explored in prior research.
Limitations:
Retrospective design may introduce bias and limit causality.
High degree of missing values for MGMT methylation status may affect results.
Findings may not be generalizable beyond the single center, and potential confounding variables were not fully addressed.
Conclusion:
Further research is needed to elucidate the role of antidepressants in glioblastoma survival, particularly focusing on specific classes, their mechanisms, and the influence of socioeconomic factors.
